Pembrolizumab plus lenvatinib in advanced endometrial cancer: case report and systematic review of lung toxicity

Frontiers in Oncology

Oncology

Caterina Riillo¹  Giacomo Rossini¹  Valentina Farenza¹  Federica Falcone¹  Antonella Crispino¹  Martina Costa¹  Mariamena Arbitrio²  Domenico Ciliberto³  Angela Salvino³  Pierosandro Tagliaferri⁴  Nicoletta Staropoli⁴  Pierfrancesco Tassone⁴  Francesco Manti⁵ 

[1] Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy;Institute for Biomedical Research and Innovation (IRIB), National Research Council of Italy (CNR), Catanzaro, Italy;Medical and Translational Oncology Unit, AOU Renato Dulbecco, Catanzaro, Italy;Medical and Translational Oncology Unit, AOU Renato Dulbecco, Catanzaro, Italy;Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy;Radiology Unit, AOU Renato Dulbecco, Catanzaro, Italy;

关键词: advanced endometrial cancer;    immunotherapy;    targeted therapy;    pembrolizumab;    lenvatinib;    lung toxicity;   

DOI  :  10.3389/fonc.2023.1145986

 received in 2023-03-15, accepted in 2023-06-07,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundThe optimal strategy for the treatment of recurrent and/or advanced endometrial cancer is still undefined. Recently, despite the lack of any predictive biomarker, the combination of pembrolizumab with lenvatinib has improved survival outcomes. We here report the long-term management of lung toxicity in a patient with endometrial cancer, and we critically review the current therapeutic options for this disease.ResultsA patient with heavily pretreated endometrial cancer took pembrolizumab plus lenvatinib for 1 year, achieving a persistent partial response with a time to treatment failure of 18 months, despite relevant lung toxicity that did not affect the remarkable overall clinical benefit. A systematic review of this combination underlines the efficacy outcome despite toxicity. Interestingly, the literature review on lung toxicity suggested the role of anti-angiogenetic agents in the pathogenesis of lung cavitation, probably related to direct treatment activity, and disclosed a potential radiological sign predictive of the activity of anti-angiogenetic agents.ConclusionWe underline the efficacy of pembrolizumab plus lenvatinib in the current treatment landscape of endometrial cancer, underscoring the relevance of a correct management of toxicity.

【 授权许可】

Unknown   
Copyright © 2023 Staropoli, Salvino, Falcone, Farenza, Costa, Rossini, Manti, Crispino, Riillo, Ciliberto, Arbitrio, Tassone and Tagliaferri